Introduction
Glycoside hydrolase family 59 (GH59) humang alactosylceramidase (GALC, galactocerebrosidase) is an 80 kDa protein responsible for the lysosomalt urnover of galactosylceramide andg alactosylsphingosine. Newly synthesized GALC contains at least four N-linked glycosylation sites, which are responsible for lysosomal trafficking through the mannose-6-phosphate receptor. [1] After enteringt he lysosomes, the enzyme is cleaved into 30 and 50 kDa subunits without effect on enzymatic activity. [2] Crystals tudies indicate that no dissociation of these subunits occurs. [3] Substrate hydrolysis by GALC occurs through aK oshland double displacementm echanism with overall retention of the b-anomericc onfiguration of the released galactopyranoside (Scheme 1A). The two carboxylic acid residuesi nt he active site that function as an ucleophile and ag eneral acid/ base have been identified as the glutamic acidr esidues E258 and E182, respectively. [1, 3] Deficiencies in GALC are at the basis of the autosomal recessive lysosomal storage disorder Krabbe disease, also termed globoid cell leukodystrophy.M ore than 70 mutationsi nt he gene encoding GALC have been implicated in the development of this disease. [1] The main pathological consequences are found in the peripherala nd central nervous systems. The Galactosylceramidase (GALC) is the lysosomal b-galactosidase responsible for the hydrolysis of galactosylceramide. Inherited deficiency in GALC causes Krabbedisease, adevastating neurological disorderc haracterizedbyaccumulation of galactosylceramide and its deacylated counterpart, the toxic sphingoid base galactosylsphingosine (psychosine). We report the design and application of af luorescently tagged activity-based probe (ABP) for the sensitive and specific labeling of active GALC molecules from various species. The probe consists of a b-galactopyranose-configured cyclophellitol-epoxide core, conferring specificity for GALC,e quipped with aB ODIPY fluorophore at C6 that allows visualization of active enzyme in cellsa nd tissues. Detection of residual GALC in patient fibroblasts holds great promise forl aboratory diagnosis of Krabbed isease.W e furtherd escribe ap rocedure for in situ imaging of active GALC in murineb rain by intra-cerebroventriculari nfusiono ft he ABP.
In conclusion, this GALC-specific ABP should find broad applications in diagnosis, drug development, and evaluation of therapyf or Krabbe disease. mechanism behind this neuropathologyh as not been fully elucidated. [1, 2] Reduced activity of GALC resultsinr educed catabolism of galactosphingolipids,i ncluding galactosylceramide and galactosylsphingosine (psychosine). Galactosylceramide is the main lipid component of myelin, the protective sheath around neuron axons that is essential for correctf unctioning of the nervouss ystem. Accumulation of the toxic metabolite galactosylsphingosine eventually leads to apoptosis of myelin-forming cells and consequentd emyelination and neurodegeneration. [4, 5] Infantile Krabbe disease is usually diagnosed before one year of age and lethal beforet he age of two years. Early symptomsi nclude limb stiffness, developmental delay,a nd severe irritability.W hen diagnosed in adolescents or adults, other symptoms can be observed, such as seizures,feeding difficulties,s lowing of mental and motor development, muscle weakness, spasticity,d eafness, and blindness. The onset and severity of symptoms, as well as the course of the disease in adult Krabbe patients, is highly variable, even in patients carrying the same mutation. [6, 7] Diagnosis can be confirmed by measuring residual GALC activity in leukocytes or cultured skin fibroblasts, which is usually 0-5 %o fn ormall evels.H owever, the amount of residual activity is neither directly correlated to the clinical symptomsn or to the course of the disease. Carriers might have as little as 10-20 %o fn ormalG ALC activity without being affected. The only availablet reatment for Krabbe disease involves symptomatic treatment and physical therapy. Clinicalt rials with hematopoietic stem cell transplantation, which aim to restoreG ALC activity in the central nervous system and therebyp reventf urtherd emyelination, hold promise in slowing the course of juvenile Krabbed isease when diagnosed at an early stage. [8, 9] Further investigations of GALC and its involvement in Krabbed isease would benefit from the availability of an activity-based probe (ABP) that specifically targets this enzyme. Numerous fluorescent b-galactosidaseprobeshave been reported in literature. However, most of these are reversiblea nd therefore cannot be used in, for example, gel-based assays. Examples include substrates consisting of a b-galactose moiety with al uminescento rf luorogenic taga ttached to the aglycon position that is released after cleavage by the enzyme, [10] [11] [12] [13] [14] [15] [16] as well as fluorescently tagged competitive inhibitors. [17, 18] In addition, af ew ABPs that enable irreversible mechanism-basedl abeling of retaining b-galactosidases have been reported. These include suicide substrates bearing al atent quinone methide precursor as the aglycon, to whichafluorescent or fluorogenic tag is attached, [19] [20] [21] [22] and 2-fluorogalactoside inhibitors in which the hydroxy group at C6 is substituted with an azide, which enablest wo-step labelingb yS taudinger-Bertozzi ligation. [23] To date, noneo ft hese probes has been used for the labeling of human retaining b-galactosidases.
Our work on activity-based retainingg lycosidasep robes used the naturalp roduct and retaining b-glucosidasei nhibitor, cyclophellitol, as starting point. [24] Substituting the epoxidef or an aziridine and grafting ar eporterg roup onto the aziridine nitrogen yielded ABPs that were broadly selectivef or various members within ag iven class of retaining glycosidases. Glycosidase family selectivity was dictated by the configurationo f the cyclophellitol aziridine derivative,a na pproacht hat was shown valid for GH1-retaining b-glucosidases,G H79-retaining a-galactosidases and, most recently, for GH29-retaining a-fucosidases. [25] [26] [27] In our first forays into activity-based glycosidase profiling,h owever,w es tudied cyclophellitol derivatives modified at C6 (glucopyranose numbering) with af luorophore. [28] These epoxide probese xhibited much highers electivity than their aziridine analogues. Because of their high selectivity and potencyf or human lysosomal glucosylceramidase( GBA)-the enzyme deficient in Gaucher patients-we now routinelyu se the fluorescent cyclophellitol derivativest om onitor GBA activity in vitro, in situ, and in vivo in healthya nd Gaucher models. [28] We realized that this probe design might also hold potential for the development of aG ALC ABP suitable for monitoring this enzyme in the context of Krabbe disease (Scheme 1B), the more so as GALC and GBA have related glycosylceramide substrates. Here we describe the evaluation of b-galactopyranoseconfigured epoxides 1-4 as inhibitors and ABPs for GALC (Scheme 1C). The cyclophellitol core of thesep robes, synthesized as reported, [24, 29, 30] was designed to mimic the substrate's terminal galactosyl moiety and bind covalently to the target enzyme through nucleophilic attack of the catalytic residue in the active site on the b-configured electrophilic epoxide moiety (Scheme 1B). The non-tagged inhibitor 1 was included in our studies as ag alactose-configured isomer of the known retaining b-glucosidase inhibitor cyclophellitol. [24, 28] For potential use in two-step activity based profiling studies, in ABP 2 the primary hydroxy group is substituted with an azide that can be used fort wo-step labeling by copper(I)-catalyzed or copper-free strain promoted alkyne-azide[ 2 + +3] cycloaddition chemistry or Staudinger-Bertozzi ligation. In addition, this probe could serve as ac ontrol probe and an inhibitor.A BPs 3 and 4 wereo btained by functionalization of 2 with aB ODIPY fluorophore and ab iotin tag, respectively.
Results

Labelingand inhibition of recombinant galactocerebrosidase
First we evaluated the ability of compounds 1-4 to inhibit recombinant GALC by measuring residual enzyme activity using the fluorogenics ubstrate 4-methylumbelliferyl b-d-galactopyranoside( 4-MU b-Gal) after 30 min of pre-incubationw ith varying concentrations of the probes. Plots of residual activity against inhibitorc oncentration reveal ac leard ose-dependent inhibition of GALC by all probes( Figure 1A) . The apparent IC 50 values calculated from these curvesa re shown in Ta ble1.T he non-tagged epoxide 1 provedt ob eaveryp otent inhibitor of GALC with an apparent IC 50 value of 38 nm.S ubstitution of the hydroxy group at the C6 position with an azide (2), however, resultedi nadramatic loss of potencyw ith an almost 2000-fold increase of the apparent IC 50 value (70 mm). We found probe 2 to reach full inhibition after ap rolonged incubation time. Interestingly,the inhibitory potency was partially restored by incorporation of aB ODIPY dye (3), but not ab iotin tag (4), at the same position. The second order rate constantsf or inhibition (k i /K i )o fc ompounds 1 and 3 were in agreement with this observation (see Table 1a nd Figure S1 in the Supporting Information). Hence, it appears that the hydrophobic fluorophore leads to enhanced bindingo ft he probe to its target enzymea nd might be better tolerated in the active site of the enzymet han as mall polar azide moiety.Asimilar result has been found previously fort he inhibition of retaining b-glucosidases by analogousC 6-modified probes, although the beneficial effect of the BODIPY dyew as much larger in that case. [28] On the contrary,p revious findings suggest that neither of the a-configured isomers of the C6-functionalized epoxide probes 2-4 appears to inhibit retaining a-galactosidases, [26] indicating that this phenomenon is dependent on the specific active site features and substrate tolerance of each individualg lycosidase.
To demonstrate the irreversibility of GALC inhibition by ABP 3 we preincubated GALC with ABP 3 fordifferent time periods. Next, residual enzymatic activity in the samples was determined and aliquots of the same samples were subjected to gel electrophoresis to quantify ABP-labeled GALC ( Figure S2 ). Figure 1A ). Second-order rate constants were calculated from progress curves over time ( Figure S1 ). n.a.:n ot assessed. ChemBioChem 2017, 18,402 -412 www.chembiochem.org
Enzymea ctivity was irreversibly lost during the pre-incubation in time-and concentration-dependentm anner.L oss of activity of GALC by pre-incubation with ABP 3 correlated with its fluorescent labeling. To further demonstrate irreversibility of labeling, we incubated GALC with ABP 3 for one hour and separated enzymea nd small compound by using as pin dialysis cartridge with 7kDa cutoff. No activity wasfound to be recovered over time after removal of free unbound ABP 3 from the enzyme ( Figure S3 ). We also incubated enzyme andA BP 3 briefly (2 min) before performing the same separation:i nt his case part of the separated enzyme population was still active. Again, the amounto fe nzyme activity did not increasef ollowing the separation from free ABP 3.A nalysis of labeled GALC revealed no loss of label following separation of pre-labeled enzyme from free ABP 3 ( Figure S3 ). In order to assess the selectivity of inhibitors 1-4 forr etaining b-galactosidases over the related class of retaining a-galactosidases, we determined inhibition of recombinant a-galactosidase A( Fabrazyme) by using as imilar assay with the fluorogenic substrate 4-methylumbelliferyl a-d-galactoside.W ed id not detecta ny inhibition after 30 min of pre-incubation with up to 100 mm of the probes(data not shown).
Having shownt hat compounds 1-4 were able to irreversibly inhibit GALC, we next assessed the visualizationo ft he recombinant enzyme on gel by using fluorescently labeled ABP 3.
Exposure to BODIPY-epoxide 3 for 1hresulted in concentration-dependentf luorescent labelingo faband around8 0kDa, corresponding to the molecular weighto fn on-dissociated GALC ( Figure 1B ). The labeling was completely abolished by denaturation of the enzyme prior to addition of the ABP,c onfirming the specific binding of the probe to catalytically active enzyme. In addition, as econd fluorescently labeled band of approximately 60 kDa wasv isible at higherp robe concentrations. This protein most likely represents serum albumin, acomponent of the cell culture medium. Unwanted labeling of albumin by BODIPY-functionalized probesc an be caused by nonspecific interactions of the hydrophobic dye with the protein.
Evidence for the non-specific nature of these interactions is provided by the fact that denaturation of the protein by boiling in assay buffer prior to labeling with ABP 3 resulted in an even stronger fluorescents ignal, which could only be eliminated by addition of the surfactant SDS. Pre-treatment of samples with non-taggedi nhibitor 1 led to complete disappearance of the fluorescent labeling of GALC by BODIPY-tagged epoxide 3,w hereas the labeling of albumin was unaffected ( Figure 1C ). Pre-incubation with azide-and biotin-tagged probes 2 and 4 resulted in partial blockingo f the fluorescent labeling of GALC. We also used biotinylated ABP 4 to visualize GALC activity directly by streptavidin western blotting( Figure 1D ). In agreement with the higherI C 50 value of this probe as compared to its fluorescently labeled analogue 3,arelatively large amount of probe is required to label the enzyme. At the highest concentration tested (10 mm), as ingle biotin-labeled band was clearly visible that corresponds to catalytically active GALC.
pH dependence of galactocerebrosidase labeling
As GALC is alysosomalenzyme, itsactivity is highest in aslightly acidic environment with an optimum around pH 4.3. [3] We examined the pH dependence of GALC labeling by BODIPYfunctionalized ABP 3 by exposing the recombinant enzyme to the probe in buffers of varyingp H( Figure 1E ). The intensity of fluorescent labeling of GALC is highest at pH 4-5, whereas it is almostc ompletely abolished at pH 3a nd lower or pH 7a nd higher.Q uantification of the fluorescent gelb ands revealed that the amount of labeling by ABP 3 overlaps perfectly with the enzymatic activity,a sd etermined by fluorogenics ubstrate hydrolysis ( Figure 1F ). These resultsi ndicate that binding of the probe occurs in an activity-based manner and support the proposed bindingm echanism depicted in Scheme 1B.
Selectivity of galactocerebrosidase labeling
Next, we set out to validate our hypothesis that selective labeling of retaining b-galactosidases and retaining b-glucosidases could be achieved with differently configured epoxide-based ABPs. For this purpose, we used b-galactosidase ABP 3 and the previously reported b-glucosidaseA BP 5 [28] (Scheme 1C)t o label either recombinant GALC or recombinantg lucocerebrosidase, al ysosomal retaining b-glucosidase. The two ABPs were functionalized with different BODIPY fluorophores and could therefore be visualized by using differents canner settingsf or in-gel fluorescent readout. Although GALC was labeled exclusively by probe 3,g lucocerebrosidase was labeled by ABP 5 but not by its stereoisomer, 3 ( Figure 1G ). Thea bsence of cross-reactivity demonstrated the selectivet argeting of each of these enzymes by the appropriately configured ABPs.
To further demonstrate the specificityo fp robe 3 towards GALC and to show its application to label endogenous enzyme, we used the probe to label varioust issue extracts of Twitcher (twi/twi)m ice. [32] These animalsa re an aturally occurring modelo fK rabbed isease and lack GALC protein. Wec ompared the labeling of tissues of wild-type (wt), Twitcher,a nd heterozygous mice with ABP 3 and ABP 5.A se xpected, labeling by b-glucosidase probe 5 occurred in all tissues of all the genotypes (Figure 2A ). However, incubation of tissue lysates with GALC probe 3 resulted in fluorescent labeling of as ingle band of approximately 50 kDa in the kidney,b rain, and sciatic nerve of wt and heterozygous animalsb ut not of Twitcher mice (Figure 2A ). This band corresponds to the 50 kDa subunit of GALC that is formed after proteolytic cleavage of the enzymei nt he lysosome.T he fact that no labeling by probe 3 was detected in wt liver is in line with the low expression levels of GALC in this organ. [33] To confirm the identity of the labeled proteins, we performed as treptavidin affinity purification after labeling of mousek idney lysates with biotinylated ABP 4.P roteins were subjected to LC-MS/MS identification following tryptic digestion. Analysis of those proteins specifically enriched in samples treated with probe as compared to the no-probec ontrol revealed the specific labelingo fs everalp eptides from the N-terminal part of the active 50 kDa GALC protein by ABP 4 (Table S1 ).
Next, we studied competitiono fA BP 3 labeling of GALC by two known competitive inhibitors of the enzyme, ABB116 [31] (Scheme 1C,c ompound 6)a nd galactosylsphingosine or psychosine( Scheme 1C,c ompound 7) . Labeling of GALC in mouse brain and kidney lysates by probe 3 wasfully competed by both inhibitors at millimolar concentrations;t his confirmed that the ABP binds to the active site of the enzyme (Figure 2B) .
BesidesG ALC, lysosomes contain another acid b-galactosidase involved in degradation of various substrates like ganglioside GM1, lactosylceramide, glycoproteins, and keratan sulfatederived oligosaccharides. [34] [35] [36] Malfunctioning of this b-galactosidase can cause GM1 gangliosidosis and Morquio Bs yndrome. [34, 37] To evaluate the enzymes pecificity of probe 3 and epoxide inhibitor 1 within the family of retaining b-galactosidases, we investigated their effect on the enzymatic activity of lysosomal acid b-galactosidasea nd GALC. To distinguish the two enzymea ctivities, we followed the protocol described by Martino et al.,w hich employs AgNO 3 as as elective competitive inhibitor of lysosomal acid b-galactosidase. [38] Pre-incubation of brain and kidney lysates with 10 mm of probe 3 resulted in as ignificant decrease in GALC activity (ca. 50 %o fu ntreated values) in theset issues,w hereas b-galactosidasea ctivity was unaltered ( Figure 2C and D) . In contrast, incubation of the lysates with 0.5 mm of inhibitor 1 completely abrogated both enzymea ctivities.
The human body contains one additional b-galactosidase in the small intestine:l actase, also knowna sl actase-phlorizin hydrolase (LPH). [39, 40] This enzyme,w hich also has b-glucosidase activity,c leaves lactose into galactose and glucose, and deficiency in its activity causes lactose intolerance. We transfected human embryonic kidney (HEK293) cells with LPH and studied labeling of the enzymeb yA BP 3 and ABP 5 by using concentrationso ft hese probesa tw hicht hey are known to target LPH ( Figure S4) . [28] Whereas the b-glucosidaseABP 5 resulted in prominentl abeling of LPH,t his was negligible for ABP 3,a gain indicating specificity of ABP 3 for binding to GALC and not LPH.
In situ and in vivoG ALC labeling
Finally,w ee xamined labeling of GALC by ABP 3 in intact cells and tissues. We notede arlier that the stereoisomer ABP 5 was Figure 2 . Labeling of tissues of wild-type, GALC-deficient (Twitcher) and heterozygous mice. A) Homogenates of brain,kidney,s ciatic nerve and liver of wt (Galc+ +/+ +), carrier (Galc+ +/À), and Twitcher( GalcÀ/À)m ice were incubated with ABP 3 (1 mm)o rA BP 5 (100 nm). Samples were analyzedby7 .5 %S DS-PAGE with fluorescentr eadout, followed by CBB staining. M: protein marker.B)Competition of ABP 3 labeling ofG ALC in mouse kidney and brain homogenates by ABB166( 6)a nd psychosine (7). C) Kidney homogenates were pre-incubated with 10 mm ABP 3 and 0.5 mm compound 1 for 1h,a fter which the residual acid b-galactosidase and GALC enzyme activity was determined. D) Brain homogenates were pre-incubated with 10 mm ABP 3 and 0.5 mm inhibitor 1 for 1h,a fter which the residual acid b-galactosidase and GALC enzymea ctivity was determined.D ata (n = 3per group, mean AE SD) were analyzed by using one-way ANO VA followed by the Dunnett's multiple comparison test:*p < 0.05;**p < 0.01;*** p < 0.001. ChemBioChem 2017, 18,402 -412 www.chembiochem.org able to penetrate cells by diffusion andefficiently labels lysosomal glucocerebrosidase in situ. [28] Cultured HEK293 cells, with and without overexpression of GALC,w ere exposed for 1hour to 5nm ABP 3,a nd confocal fluorescencem icroscopy was used to detect labeled GALC in the unfixedc ells. The fluorescent labeling in control HEK293 cells was low ( Figure 3A ), in agreement with the virtual absence of endogenous GALC labeling in HEK cells extracts (FigureS4). Lowe xpression levels of GALC were furtherc onfirmed by western blot (not shown). However,i nc ells overexpressing GALC, ap erinuclear vesicular labeling,c haracteristic of lysosomes, was observed ( Figure 3A) . The perinuclear vesicular labeling pattern of lysosomes was confirmed by labeling of fixed cells with the lysosomal marker LAMP1 ( Figure 3A,l ast panel) .
Next, we examined ABP 3 labeling of endogenous GALC in the brain of living mice. For this purpose, we intra-cerebroventricularlyi nfused mice for 2h with 1nm ABP 3.T he animals were sacrificed, and brain slices were examined by confocal fluorescencem icroscopy. Pronounced perinuclear labeling was detected in cells of the cerebellar cortex,o verlapping with immuno-histochemical detectiono fG ALC and lysosomal marker LAMP1 ( Figure 3B) .
To investigate the potential of ABP 3 for the diagnosis of Krabbed isease, we labeled fibroblasts from Gaucher and Krabbed isease patients andh ealthy volunteers simultaneously with ABP 3 and ABP 5.L abeling was preceded by an affinity purification of glycosylated proteins with concanavalin A beads. Ab and of approximately 50 kDa, corresponding to human GALC, was labeled by ABP 3 in fibroblasts of the control subjects and Gaucher disease patients ( Figure 4 ) but was virtually absent in samples from individuals diagnosed with Krabbed isease. As expected, activeG BA labeled by ABP 5 was much less prominent in fibroblasts of Gaucher disease patients compared to the other cell types (Figure 4 ).
Discussion and Conclusion
Prompted by the successful design of b-glucopyranose-configured epoxide-based probes that are able to label lysosomal glucocerebrosidase (E.C. 3.2.1.45)i na na ctivity-based manner with high selectivity and sensitivity, [28] we examined as imilar approachf or the related enzymeg alactocerebrosidase (E.C. 3.2.1.46). The b-galactopyranose-configured epoxide-based probes 1-4 were demonstrated to inhibit recombinant and endogenous rodentG ALC covalently and irreversibly.O ft hese probes, non-tagged epoxide inhibitor 1 was the mostp otent inhibitor.S ubstitution of the hydroxy group at C6 with an azide (2)r esulted in loss of potency,w hereas installment of aB ODIPY tag at the same position (3)p artiallyr estored the inhibitory potency.Ah igh-resolution crystal structure of murine GALC was recently reported. [3] Soaking of crystallized enzyme with ABP 3 should yield an explanation for the noted differences in affinity of inhibitor 1 and ABPs 2-4.
BODIPY-functionalized ABP 3 and biotinylated ABP 4 enable the visualizationo fc atalytically active GALC on gel. The epoxide probesl abel the enzymei na na ctivity-based manner.T he selectivity of the labeling by ABP 3 is remarkable.I np articular, BODIPY-epoxide 3 differs only in the configuration of as ingle substituent from the previously reported glucopyranose configured stereoisomer 5,y et the two probes enables elective targeting of GALC and glucocerebrosidase, respectively.A tl ow concentrations, ABP 3 targets neither the relatedg lycosidase a-galactosidase An or,i mportantly,a ny of the other retaining b-g alactosidases known to be present in humans, lysosomal acid b-galactosidase (EC 3.2.1.24) and intestinal LPH( E.C. 3.2.1.106). We previously noted the same high degree of selectively for BODIPY-functionalized b-g lucopyranose-configured epoxide 5. [28] At low concentration,t his probe selectively labeled lysosomal glucocerebrosidase but not the non-lysosomal glucosylceramidaseG BA2, cytosolic b-glucosidase GBA3, and LPH, [28] all other enzymes degrading glucosylceramide. GALC is synthesized as ap recursor of about 80 kDa that is processed into 30 and 50 kDa fragments after lysosomal uptake. The two fragments do not dissociate but remainlinked to each other by disulfide bridges. [1] The cleavage of the already active8 0kDa precursor does not affect the enzymatic activity. [41] In line with this, we found that ABP 3 labels recombinantly produced 80 kDa precursor GALC well. In lysates of GALC-overexpressing HEK293 cells, we could detect both the 80 kDa precursor and the 50 kDa mature subunit with ABP 3 (data not shown). The5 0kDa GALC subunit, containing the catalytic nucleophile residue E258, was the major GALC form visualized with ABP 3 in kidney, brain, and sciatic nerve of wt and heterozygousm icea nd is absent in the same tissues of Twitcher animals.
Importantly,t he reported b-galactopyranose-configured epoxide-based probesc an be applied as diagnostic tools in monitoring Krabbed isease by visualizing the levels of residual GALC activity,a sw as demonstrated here by the labeling of active enzymei nc ontrolc ompared to Krabbe disease fibroblasts. The probesc ould also be used in activity-based protein profiling studies, aiding in the developmento fn ovel therapeutic strategies by facilitating the screening of potential chaperones interacting with the catalytic pocket of GALC. Last but not least, the probes will likely prove of great value to evaluate efficacyo fe xperimental therapiesi nm ouse modelso fK rabbe disease.
Experimental Section
Synthesis of b-galactopyranose-configured epoxide-based probes: b-Galactopyranose-configured cyclophellitol epoxides 1-4 were synthesized as previously reported. [24] Enzymes: Recombinant murine GALC was expressed in HEK293 cells, as previously described. [1] The mouse enzyme is 83 %homolo-gous to human GALC. [1] Culture medium containing the secreted recombinant protein was used directly for fluorogenic substrate assays and labeling assays. Recombinant a-galactosidase A( Fabrazyme) and recombinant b-glucocerebrosidase (Cerezyme) were obtained from Genzyme.
Cells: HEK293 cells (ATCC CRL 1573) were cultured in Dulbecco's Modified Eagle Medium (DMEM) with high glucose (Gibco), supplemented with 10 %F BS (Bodinco) and 100 units mL À1 penicillin/ streptomycin (Gibco). HEK293 cells with and without stable overexpression of murine GALC were generated as previously described. [1] Animals: Twitcher mice (twi/twi), an atural model of Krabbe disease resulting from am utation in the GALC gene, along with wildtype littermates, were generated by crossing heterozygous ( + /twi) mice in-house. Heterozygous C57BL/6J B6.CE-Galc twi /Jm ice (stock number 000 845) were obtained from the Jackson Laboratory (Bar Harbor,U SA). Mouse pups were genotyped as previously described. [33] Mice (AE 3w eeks old) received the rodent AM-II diet (Arie Blok Diervoeders, Woerden, The Netherlands). Animals were housed and experiments were conducted according to protocols approved by the Institutional Animal Welfare Committee of the Academic Medical Centre Amsterdam in the Netherlands.
Twelve week-old wt C57Bl/6 mice underwent intra-cerebroventricular (i.c.v.) administration of ABP 3.The animals were kept in individual cages at constant temperature (23 AE 2 8C) and a1 2/12 hl ight/ dark cycle. They were exposed to ad libitum food and water before and after the experimental procedures.
Fibroblasts: Fibroblasts were obtained from skin biopsies with informed and signed consent from the donors.
Expression and labeling of human lactase phlorizin hydrolase (LPH): Primers were designed based on NCBI reference sequence NG_008104.2. The full-length cDNA sequence was cloned into pcDNA3.1 in frame with the myc/His vector (Invitrogen). Confluent HEK293 cells were transfected with empty pcDNA3.1 vector or the vector with the described insert, in conjunction with FuGENE (Roche), and harvested after 72 hb ys craping into potassium phosphate (KPi)b uffer (25 mm,p H6.5) supplemented with 0.1 %( v/v) Figure 4 . Labeling of Gaucher and Krabbe patient fibroblastswith ABPs 3 and 5.Fibroblasts from Gaucher and Krabbe disease patients, and healthy volunteerw ere lysed and incubated overnight with concanavalin Abeads for enrichment of glycosylated proteins. Bead-bound GALC was labeled with ABP 3( 1mm), followed by labeling of GBA with ABP 5 (0.1 mm). Samples were resolved by 10 %S DS-PAGE with fluorescent readout, followed by CBB staining. M: protein marker. ChemBioChem 2017, 18,402 -412 www.chembiochem.org Triton X-100 and protease inhibitor cocktail (Roche). Av olume equivalent to 50 mgofprotein was labeled with 1 mm (final concentration) of ABP 3 or ABP 5 for 2hat 37 8C.
SDS-PAGE analysis and fluorescence scanning: Protein samples (recombinant enzyme, cell and tissue homogenate) were denatured by adding 5 Laemmli sample buffer containing 2-mercaptoethanol ( 1 = 4 of sample volume) and boiling for 4min at 100 8C. The samples were then run on a7 .5 %o r1 0% SDS-PAGE gel, and wet slab gels were scanned for fluorescence by using aT yphoon Variable Mode Imager (Amersham Biosciences, Piscataway,N J, USA) with l ex = 488 nm and l em = 520 nm (band pass:4 0) for green fluorescent ABP 5 and l ex = 532 nm and l em = 610 nm (band pass:3 0) for red fluorescent ABP 3.A saloading control, gels were stained with Coomassie Brilliant Blue (CBB) and destained with milliQ water.
Western blotting: Proteins were transferred onto aP VDF membrane by using aB io-Rad Trans-Blot Turbo Transfer System. Membranes were blocked with 1% BSA in Tris-buffered saline (TBS) with 0.1 %T ween-20 (TBST) for 1h at room temperature, hybridized with streptavidin-horseradish peroxidase (HRP) for 1h at room temperature (1:10 000 in blocking buffer) (Molecular Probes, Life Te chnologies), washed with TBST and TBS, and then visualized by using an ECL + western blotting detection kit (Amersham Biosciences). Protein standards were PageRuler Plus Prestained Protein Ladder (Thermo Scientific) and biotinylated protein marker (BioRad).
Proteomics: One kidney from af ive week old wt mouse was homogenized in 150 mm McIlvaine buffer,p H4.5 supplemented with protease inhibitors. The homogenate (100 mL, containing 3.5 mg protein) was incubated for 2h at 37 8Cw ith ABP 4 (100 mL, 0.18 mm)i nM cIlvaine buffer (150 mm,p H4.5). Analysis was performed as previously reported. [42] Peptides were desalted on stage tips [43] and analyzed with at rap-elute system on aC 18 reversedphase nano LC with a4 5min 10-60 %ACN/0.1 %f ormic acid gradient and aT hermo LTQ-Orbitrap mass spectrometer by using a top 3d ata-dependent protocol (60 000 resolution, m/z range 300-2000, 1000 ms fill time in the Orbitrap, 35 units of CID energy for MS/MS fragmentation, 120 ms max fill time, AGC 50 e3, and 750-count threshold). Ions of z = 2+ + and higher were selected to be fragmented twice within 10 s, prior to exclusion for 150 s. Peak lists were extracted and searched against the Uniprot mouse (decoy) database, with carbamidomethylation of cysteine as af ixed modification and oxidation of methionine as av ariable modification, 20 ppm peptide tolerance, trypsin as protease, and with two missed cleavages allowed by using aM ascot (matrix science) search engine. . After incubation at 37 8Cf or 20 min, the reaction was quenched glycine (0.3 m) adjusted with NaOH to pH 10.6, and fluorescence was measured by using an LS55 fluorimeter (PerkinElmer) with l ex = 366 nm and l em = 445 nm. All samples were corrected for background fluorescence (sample without enzyme), and residual enzyme activity was calculated as compared to ac ontrol sample incubated in the same manner but without inhibitors.
In vitro labeling assays with recombinant GALC: In at ypical experiment, culture medium containing recombinant GALC (5 mL) was diluted with McIlvaine buffer (pH 4.3)/H 2 O( 2:1, v/v,1 4mL) and exposed to the indicated concentrations of ABPs 3 or 4 (1 mLo f a2 0 solution in DMSO) for 1h at 37 8C. Labeling of denatured enzyme was performed by pre-heating the enzyme to 100 8Cf or 3min in buffer with or without 1% SDS (9 mLt otal volume) before addition of the probes. One half of each sample was resolved on 10 %S DS-PAGE. In-gel visualization of the fluorescent labeling by probe 3 was performed directly on the wet gel slabs. In the case of probe 4,b iotinylated proteins were detected by performing streptavidin western blotting.
Competition assays: Culture medium containing recombinant GALC (5 mL) in McIlvaine buffer (pH 4.3)/H 2 O( 2:1, v/v;1 4mL) was first exposed for 1h at 37 8Ct oe ither 1 (0.2 mm), 2 (10 mm), or 4 (10 mm,a ll 1 mLo f2 0 solution in DMSO), before labeling with 3 (0.2 mm, 1 mLo f4mm stock in DMSO) as described above. [28] (1 mLo f 10 mm stock in DMSO) for 1h at 37 8C. The reaction mixtures were then resolved on 7.5 %S DS-PAGE, and in-gel visualization of the fluorescent labeling was performed directly on the wet gel slabs.
In vitro labeling assay with mouse tissue homogenates: Animals were first anesthetized with ad ose of Hypnorm (0.315 mg mL www.chembiochem.org phenyl citrate and 10 mg mL À1 fluanisone) and Dormicum (5 mg mL À1 midazolam). The given dose was 80 mL/10 gb ody weight. Animals were sacrificed by cervical dislocation. Tissues were collected, snap frozen in liquid N 2 and stored at À80 8C. Later, homogenates from the frozen material were made in KPi buffer (25 mm,p H6.5), supplemented with 0.1 %( v/v)T riton X-100 and protease inhibitors, and protein concentration was determined (BCA kit, Pierce). For labeling experiments, av olume of tissue homogenate equivalent to 50 mg( for kidney,b rain and liver) or 25 mg of protein (for sciatic nerve) was completed to 10 mLw ith water and incubated for 30 min at 37 8Cw ith 1 mm of ABP 3 (10 mL2mm in McIlvaine buffer 150 mm pH 4.3) or 100 nm of ABP 5 (10 mL 200 nm in McIlvaine buffer 150 mm pH 5.2, 0.2 %(w/v)sodium taurocholate, 0.1 %( v/v)T riton X-100). The samples were then resolved on 7.5 %S DS-PAGE and analyzed as described above. For competition experiments the indicated concentrations of psychosine (7) and ABB166 (6)d issolved in water were pre-incubated with the tissue lysate for 30 min on ice before addition of ABP 3 (final concentration 1 mm)and subsequent incubation at 37 8Cf or 15 min.
Fluorogenic substrate assay with mouse tissue homogenates: For measurement of b-galactosidase and b-galactocerebrosidase activity,w ef ollowed the protocol previously described by Martino et al. [38] with slight alterations. Briefly,av olume of tissue lysate equivalent to 7.5 mgo fp rotein was completed with water (6.25 mL total volume) and exposed to the indicated concentration of ABP 3 or inhibitor 1 (6.25 mLo fa2 solution in McIlvaine buffer,p H4.3) for 60 min at 37 8C. Afterwards, AgNO 3 (12.5 mLo f1 10 mm solution in water;1 1mm)a nd substrate mix (100 mL, 0.23 mg mL À1 4-methylumbelliferyl-b-d-galactopyranoside in McIlvaine pH 4.3) were added, and the mixture was incubated for 45 min (for b-galactosidase) or 90 min (for GALC) at 37 8C. The reaction was then quenched with glycine (0.3 m) adjusted with NaOH to pH 10.6, and the fluorescence was measured with af luorimeter as described above. Data (n = 3p er group) represent mean AE SD. Statistical analysis was performed by using one-way ANOVA, followed by Dunnett'stest.
ABP intra-cerebroventricular administration: For this purpose, we followed ap reviously described procedure. [44] Briefly,i ntra-cerebroventricular stainless steel guide cannulas were implanted in the lateral ventricle by using the following stereotaxic coordinates: AP 0.3, L + 1.0, and VÀ2.2. After ar ecovery period of seven days, aneedle connected to atube was introduced in the guide cannula, and as olution of ABP 3 (1 nm in PBS) was administered at ar ate of 0.1 mLmin À1 for 10 min. After 2h,t he animals were sacrificed by CO 2 euthanasia and transcardially perfused with 250 mL of 0.9 %o f saline solution. Brains were isolated and immediately frozen for further biochemical and histological analysis.
Fluorescent and immuno-histochemical analysis of brain sections: Brains were cut in 30 mms lices with ac ryostat and attached to SuperFrost slides (Thermo Scientific). All of the following steps were performed in the dark to protect the fluorescence of the ABP. Slides were extensively washed in 0.01 m TBS to remove non-specific fluorescence and were covered in DAPI (Vector Lab, Burlingame, USA) mounting media.
For the immuno-histological analysis, brain slices were also extensively washed in TBS and then incubated overnight in TBS with 0.5 %( v/v)T riton X-100, 0.025 %( v/v)g elatin, and rabbit-raised primary antibodies against LAMP1 (Millipore) and GALC (12887-1-AP, Proteintech, Chicago, IL, USA) at ac oncentration of 1:1000. After primary antibody incubation, slides were incubated for 2h with the appropriate secondary antibodies (1:1000) conjugated with fluorescent dyes:donkey anti-rabbit Alexa 488/Alexa 594 (Life Te chnologies). The slides were then rinsed three times with TBS, mounted, and covered with DAPI to be observed in ac onfocal laser scanning microscope (Leica SP5). Images were taken with l ex = 488 nm for Alexa 488 and 561 nm for Alexa 594 and ABP 3.T o capturing images, a6 3 objective was used. In the case of singlecell images, afurther threefold magnification was used.
Fluorescence microscopy: HEK293 cells with and without stable overexpression of murine GALC were cultured on glass slides precoated with poly-l-lysine. Cells were incubated with ABP 3 (5 nm) in the medium for 1h.N ext, the cells were washed twice with PBS, and new medium was added. The cells were placed in the incubator overnight (approximately 16 h) before being washed again and then mounting the glass slides without fixation. For LAMP1 staining, the cells were fixed with 3% paraformaldehyde (v/v)b efore being washed and blocked in donkey serum. Afterwards, the cells were stained with LAMP1 antibody for 1h,w ashed and incubated with the secondary Alexa 594-conjugated antibody (see above). The cells were observed by using ac onfocal laser scanning microscope (Leica SP5) as described previously. [25] Fibroblast concanavalin Aa ffinity purification and ABP labeling: Cell pellets (from T-75 cm 2 flasks) of fibroblasts from patients and healthy volunteer were lysed in KPi buffer (pH 6.5, 100 mL, 25 mm), supplemented with 0.1 %( v/v)T riton X-100 and protease inhibitors. 
